<DOC>
	<DOCNO>NCT02929342</DOCNO>
	<brief_summary>The purpose study well define absorption elimination pathway , circulate metabolite Pitolisant steady state use Pitolisant radiolabelled , healthy CYP2D6 genotyped male subject .</brief_summary>
	<brief_title>Study Assess Absorption , Distribution , Metabolism Excretion ( ADME ) 14C-Pitolisant Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male age 30 65 year . Body mass index 18.0 35.0 kg/m2 . Genotyped regard CYP2D6 status . Participation clinical research study within previous 3 month Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study . Regular alcohol consumption male &gt; 21 unit per week . Current smoker smoke within last 12 month . Evidence renal impairment screening , indicate estimate creatinine clearance ( CLcr ) &lt; 90 mL/min use CockcroftGault equation . Use CYP2D6 inhibitor inducer 28 day prior IMP administration</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>